The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics

Hamed Samavat, Allison M. Dostal, Renwei Wang, Sarah Bedell, Tim H. Emory, Giske Ursin, Carolyn J. Torkelson, Myron D. Gross, Chap T. Le, Mimi C. Yu, Chung S. Yang, Douglas Yee, Anna H. Wu, Jian Min Yuan, Mindy S. Kurzer

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Purpose: The Minnesota Green Tea Trial (MGTT) was a randomized, placebo-controlled, double-blinded trial investigating the effect of daily green tea extract consumption for 12 months on biomarkers of breast cancer risk. Methods: Participants were healthy postmenopausal women at high risk of breast cancer due to dense breast tissue with differing catechol-O-methyltransferase (COMT) genotypes. The intervention was a green tea catechin extract containing 843.0 ± 44.0 mg/day epigallocatechin gallate or placebo capsules for 1 year. Annual digital screening mammograms were obtained at baseline and month 12, and fasting blood and 24-h urine samples were provided at baseline and at months 6 and 12. Primary endpoints included changes in percent mammographic density, circulating endogenous sex hormones, and insulin-like growth factor axis proteins; secondary endpoints were changes in urinary estrogens and estrogen metabolites and circulating F2-isoprostanes, a biomarker of oxidative stress. Results: The MGTT screened more than 100,000 mammograms and randomized 1,075 participants based on treatment (green tea extract vs. placebo), stratified by COMT genotype activity (high COMT vs. low/intermediate COMT genotype activity). A total of 937 women successfully completed the study and 138 dropped out (overall dropout rate = 12.8 %). Conclusions: In this paper we report the rationale, design, recruitment, participant characteristics, and methods for biomarker and statistical analyses.

Original languageEnglish (US)
Pages (from-to)1405-1419
Number of pages15
JournalCancer Causes and Control
Volume26
Issue number10
DOIs
StatePublished - Oct 14 2015

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health/National Cancer Institute (Grant R01 CA127236); the Department of Defense/U.S. Army Medical Research and Materiel Command (Award Number W81XWH-11-1-0013); National Cancer Institute (Award Number T32CA132670); and the Minnesota Agricultural Experiment Station (Project #MIN-18-103). Also, research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (Award Number UL1TR000114) and Cancer Center Support Grant National Institutes of Health/National Cancer Institute (P30 CA077598). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2015, Springer International Publishing Switzerland.

Keywords

  • Breast cancer
  • Green tea
  • Mammographic density
  • Postmenopausal women
  • Sex hormones

Fingerprint

Dive into the research topics of 'The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics'. Together they form a unique fingerprint.

Cite this